Literature DB >> 11392628

Muscarinic receptors and gastrointestinal tract smooth muscle function.

R M Eglen1.   

Abstract

Over the last decade, several lines of evidence have shown that both muscarinic M2 and M3 receptors are postjunctionally expressed in many smooth muscles, including the gastrointestinal tract. Although in vitro data suggests that both receptors are functional in that they inhibit adenylate cyclase activity and activate non-selective cation channels, few studies support a role in vivo. Thus, data from procedures that ablate the signaling pathway of the muscarinic M2 receptor, including receptor antagonism, pertussis toxin pretreatment reveal little effect on gastrointestinal smooth muscle responsiveness to muscarinic agonists. Recently, information from knockout mice, lacking either M2 or M3 receptor, indicate reveal a role for both subtypes. However, the contribution of the M2 receptor appears greater in the ileum than in the urinary bladder. Therapeutically, non-selective, as well as selective M3 receptor antagonists are being clinically studied, although it remains to be shown which is the optimal approach to disorders of smooth muscle motility.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11392628     DOI: 10.1016/s0024-3205(01)01054-2

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  23 in total

1.  Characterization of pre- and postsynaptic muscarinic receptors in circular muscle of pig gastric fundus.

Authors:  Pascal G Leclere; Romain A Lefebvre
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

Review 2.  Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.

Authors:  Paul Abrams; Karl-Erik Andersson; Jerry J Buccafusco; Christopher Chapple; William Chet de Groat; Alison D Fryer; Gary Kay; Alan Laties; Neil M Nathanson; Pankaj Jay Pasricha; Alan J Wein
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

Review 3.  Regulation of gastrointestinal motility--insights from smooth muscle biology.

Authors:  Kenton M Sanders; Sang Don Koh; Seungil Ro; Sean M Ward
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-09-11       Impact factor: 46.802

Review 4.  Irritable bowel syndrome: recent and novel therapeutic approaches.

Authors:  Viola Andresen; Michael Camilleri
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Cholinergic activation of enteric glia is a physiological mechanism that contributes to the regulation of gastrointestinal motility.

Authors:  Ninotchska M Delvalle; David E Fried; Gretchen Rivera-Lopez; Luke Gaudette; Brian D Gulbransen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-06-21       Impact factor: 4.052

Review 6.  Current and novel therapeutic options for irritable bowel syndrome management.

Authors:  M Camilleri; V Andresen
Journal:  Dig Liver Dis       Date:  2009-08-08       Impact factor: 4.088

7.  Effect of areca on contraction of colonic muscle strips in rats.

Authors:  Dong-Ping Xie; Wei Li; Song-Yi Qu; Tian-Zhen Zheng; Ying-Li Yang; Yong-Hui Ding; Yu-Ling Wei; Lian-Bi Chen
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

8.  Mechanisms mediating cholinergic antral circular smooth muscle contraction in rats.

Authors:  Helena-F Wrzos; Tarun Tandon; Ann Ouyang
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

9.  The use of occupation isoboles for analysis of a response mediated by two receptors: M2 and M3 muscarinic receptor subtype-induced mouse stomach contractions.

Authors:  Alan S Braverman; Ronald J Tallarida; Michael R Ruggieri
Journal:  J Pharmacol Exp Ther       Date:  2008-03-13       Impact factor: 4.030

10.  Mechanisms involved in carbachol-induced Ca(2+) sensitization of contractile elements in rat proximal and distal colon.

Authors:  Tadayoshi Takeuchi; Masahiko Kushida; Nobue Hirayama; Muneyoshi Kitayama; Akikazu Fujita; Fumiaki Hata
Journal:  Br J Pharmacol       Date:  2004-05-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.